Email updates

Keep up to date with the latest news and content from Journal of Biomedical Science and BioMed Central.

Journal App

google play app store

MST logoThe cost of publication in Journal of Biomedical Science is borne by the Ministry of Science and Technology, Taiwan.

Open Access Highly Accessed Review

Current progress in dengue vaccines

Shu-Wen Wan12, Chiou-Feng Lin123, Shuying Wang12, Yu-Hung Chen4, Trai-Ming Yeh25, Hsiao-Sheng Liu12, Robert Anderson126 and Yee-Shin Lin12*

Author Affiliations

1 Department of Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan

2 Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan, Taiwan

3 Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan

4 Department of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan

5 Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University Medical College, Tainan, Taiwan

6 Departments of Microbiology & Immunology and Pediatrics, and Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada

For all author emails, please log on.

Journal of Biomedical Science 2013, 20:37  doi:10.1186/1423-0127-20-37

Published: 13 June 2013

Abstract

Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

Keywords:
Dengue; Immunopathogenesis; Vaccine